Tracy Lively
YOU?
Author Swipe
View article: Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial
Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial Open
BACKGROUND: Black race is associated with worse outcomes in early breast cancer. We evaluated clinicopathologic characteristics, the 21-gene recurrence score (RS), treatment delivered, and clinical outcomes by race and ethnicity among wome…
View article: Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival.
Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival. Open
BACKGROUND: The 21-gene recurrence score (RS) assay (Oncotype DX) is used to guide adjuvant chemotherapy use for patients with hormone receptor-positive, HER2 (human epidermal growth factor receptor 2)-negative, axillary node-negative brea…
View article: Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival
Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival Open
The 21-gene RS is prognostic for distant recurrence and overall survival in early breast cancer. A model integrating the 21-gene RS and clinicopathologic factors improved estimates of distant recurrence risk compared with either used indiv…
View article: Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer Open
Prior studies with the use of a prospective–retrospective design including archival tumor samples have shown that gene-expression assays provide clinically useful prognostic information. However, a prospectively conducted study in a unifor…
Criteria for the use of omics-based predictors in clinical trials: Explanation and elaboration Open
The US National Cancer Institute (NCI), in collaboration with scientists representing multiple areas of expertise relevant to ‘omics’-based test development, has developed a checklist of criteria that can be used to determine the readiness…
View article: Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial
Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial Open
Background Black race is associated with worse outcomes in early breast cancer. We evaluated clinicopathologic characteristics, the 21-gene recurrence score (RS), treatment delivered, and clinical outcomes by race and ethnicity among women…
View article: Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy Open
ClinicalTrials.gov identifier: NCT00310180.
View article: Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer Open
Clinical-risk stratification provided prognostic information that, when added to the 21-gene recurrence score, could be used to identify premenopausal women who could benefit from more effective therapy. (Funded by the National Cancer Inst…
Use of Next-Generation Sequencing Tests to Guide Cancer Treatment: Results From a Nationally Representative Survey of Oncologists in the United States Open
Purpose There are no nationally representative data on oncologists’ use of next-generation sequencing (NGS) testing in practice. The purpose of this study was to investigate how oncologists in the United States use NGS tests to evaluate pa…
View article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer Open
Adjuvant endocrine therapy and chemoendocrine therapy had similar efficacy in women with hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer who had a midrange 21-gene recurrence score, although some benefit of c…
View article: Biomarkers in Early-Phase Trials: Fundamental Issues
Biomarkers in Early-Phase Trials: Fundamental Issues Open
Biomarkers are frequently being included in early-phase clinical trials. This article is meant to introduce clinical investigators to the fundamentals of choosing a biomarker test for use in an early phase trial. Steps to consider are brie…
Circulating Tumor DNA Assays in Clinical Cancer Research Open
The importance of circulating free DNA (cfDNA) in cancer clinical research was recognized in 1994 when a mutated RAS gene fragment was detected in a patient's blood sample. Up to 1% of the total circulating DNA in patients with cancer is c…